The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073) — Paolo Preziosa (2017) | RDL Network
The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)
Article 2017 en
Authors
PP
Paolo Preziosa
MR
Maria A. Rocca
GR
Gianna Carla Riccitelli
Abstract
1 min read
To compare the effects of natalizumab (NAT) and fingolimod (FTY) on clinical and MRI measures in relapsing-remitting (RR) MS patients after two years of treatment.
Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi
Discussion(0)
No comments yet. Be the first to comment.